For the quarter ending 2025-09-30, TXMD had $1,046K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Impairment of long-lived assets (note 4) | - | 0 |
| Net loss from continuing operations | 50 | -91 |
| Depreciation and amortization | 96 | 191 |
| Write-off of patents | 31 | 88 |
| Share-based compensation | 0 | 24 |
| Other | 217 | 370 |
| Other assets | -529 | -872 |
| Prepaid and other current assets | -4 | 192 |
| Accounts payable | -87 | 92 |
| Accrued expenses and other current liabilities | 425 | 84 |
| Lease liabilities | -307 | -445 |
| Other non-current liabilities | 41 | 87 |
| Total adjustments | 949 | 1,171 |
| Net cash provided by continuing operating activities | 999 | 1,080 |
| Net cash used in operating activities | 47 | -70 |
| Net increase in cash | 1,046 | 1,010 |
| Cash and cash equivalents at beginning of period | 5,059 | - |
| Cash and cash equivalents at end of period | 7,115 | - |
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)